Galapagos Says ‘No’ to SpinCo and Instead Will Seek Deals for All Assets

Galapagos Says ‘No’ to SpinCo and Instead Will Seek Deals for All Assets

Galapagos has dropped plans for a business separation that would have enabled the legacy company to focus exclusively on developing new cancer cell therapies. Instead, Galapagos said it will pursue strategic alternatives for its assets. The post Galapagos Says ‘No’ to SpinCo and Instead Will Seek Deals for All Assets appeared first on MedCity News.

Galapagos changes its mind on its big shakeup

Today's biotech news spans new leadership at UnitedHealth, Elizabeth Holmes' partner's new startup, and RA Capital layoffs.

Galapagos backtracks on planned split

Having now appointed Henry Gosebruch as CEO of the intact company, Galapagos says its priorities are exploring strategic options and “transformative” deals.

Galapagos drops plan to split after 'market developments'

Shortly after announcing a plan to separate its drug and cell therapy businesses into two separate companies, Galapagos has had a change of heart

Updated: To spin off or not to spin off? Galapagos backpedals on separation plans, CEO Paul Stoffels exits early

A month ago, former AbbVie and Neumora executive Henry Gosebruch was named the CEO of Galapagos' planned spinout, which would be handed €2.45 billion to hunt for drug candidates and build a ...

11:09 Barely four months after the announcement of the split of biotech company Galapagos, the board of directors is going to 'review' the entire operation. CEO Paul Stoffels is stepping down with immediate effect and w...